CTOs on the Move

TransCode Therapeutics

www.transcodetherapeutics.com

 
TransCode is an emerging RNA oncology company created on the belief that cancer can be defeated through the intelligent design and effective delivery of RNA therapeutics. The Company has created a platform of drug candidates designed to target a variety of tumor types with the objective of significantly improving patient outcomes. The Company`s lead therapeutic candidate, TTX-MC138, is focused on treating metastatic cancer, which causes approximately 90% of all cancer deaths representing over nine million deaths per year worldwide. The Company believes that TTX-MC138 has the potential to produce regression without recurrence in a range of cancers, including breast, pancreatic, ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details
Zdravka Medarova
 Chief Technology Officer Profile

Similar Companies

Draximage

Draximage is a Kirkland, QC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

PamLab

Pamlab, L.L.C. is a company focused on the future. We lead the United States with use of novel folate therapies to lower homocysteine. We are looking for hard-working, motivated and optimistic individuals who would like a challenging career and are

Keeps

Keeps is the first brand from Thirty Madison, which is rebuilding the healthcare experience for the modern consumer.

Arena Pharmaceuticals

We are a biopharmaceutical company focused on developing novel, small molecule drugs with optimized receptor pharmacology designed to deliver broad clinical utility across multiple therapeutic areas. Our proprietary pipeline includes potentially first- or best-in-class programs for which we own global commercial rights. Arena is headquartered in San Diego, CA, with operations in Boston, MA, and Zug, Switzerland.

OVP HEALTH

HEALTHIER. COMMUNITY. OVP HEALTH provides an extensive range of addiction treatment services, emergency department and hospitalist staffing and management services.